InstaPill® is A Globally Recognized Contract Development And
Manufacturing Organization Specializing In Orally Disintegrating
Tablets Using Our Proprietary InstaPill® Technology Platform.
Meet Us At CPHI Milan 2026
Booth No.– 12A41
October 06 – 08, 2026
CPHI Worldwide 2026 · Fiera Milano
Advanced Lyophilized Orally Disintegrating Tablets
The process starts as a liquid dose, dispensed into blister cavities, then flash-frozen and freeze-dried until only a porous tablet structure remains. That structure pulls in saliva the moment it touches the tongue, so the tablet breaks down in seconds without a sip of water.
Meet the Leadership Team at CPHI Milan 2026
Ankit Gupta
Chief Executive Officer
Rosaleen McLaughlin
Chief of the Scientific Advisory Board
Balaji Sathurappan
Head, Formulation Development
Keith Dodson
Vice President – Global Business Development (North America & UK)
Kamal Preet
Vice President – Global Business Development (Europe & Rest of World)
Piyali Ghosh
Deputy Manager, Business Development (SEA, MENA & LATAM)
Ganesh Sreesakumar
Sr Manager, Business Development (UK)
Atharva Shejwal
Assistant Manager, Business Development
Manoj Kumar Jhadav
Head, Supply Chain Management
Why InstaPill ?
Dissolves in 3–10 seconds- Ideal choice for thermolabile products
- 0.06 mg to 200 mg dose range for customize portfolio
- Fully automated integrated line with Electronic Batch Records
- No human intervention – for compliance & safety
Unique Platform with Integrated Technology
Platform features
- Taste masking and superior dispersion
- Reduced numbers of excipients compared to conventional ODTs
- 100% Automation with digital documentation
Regulatory accreditations
- Manufacturing facility in Bangalore, India approved by USFDA, EMA, TGA & Health Canada
Development capabilities
- Full QbD (Quality by Design) approach from TPP (Target Product Profile) to validated approach
- R&D centre at Bangalore, India
